Disruption of BAFF-BCR crosstalk in CLL

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML

Blood thinners a risk with cancer-associated venous thromboembolism

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism

ZUMA 1: CD19 CAR T cells for refractory NHL

400mg imatinib as good as 800mg for 10 year CML survival

Carfilzomib combinations in ENDEAVOR and FORTE

Deep molecular response to gilteritinib in CHRYSALIS trial

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Diverse T lymphocyte population fights leukaemia more effectively

Delayed exposure to common infections causes acute childhood leukaemia

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL